Jimmy Johannes, MD
Pulmonary Disease · Long Beach, CANPI 1275837205
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,097 of the $8,046 with a category attached, or 75.8%. 42 manufacturers reported payments, led by Noah Medical Corporation at 27.0% of the total.
Across 233 payments — averaging $34.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Noah Medical Corporation$2K
- GSK$1K
- AstraZeneca$576
- Boehringer Ingelheim$533
- Regeneron Healthcare Solutions, Inc.$509
- Vertex$437
- plus $3K from 36 others
Across 155 payments — averaging $15,133 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$1.3M
- Regeneron$1M
- Mylan Inc.$2K
What the payments were for
- Travel & lodging$1,90124%
- Food & beverage$6,09776%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GALAXY$962
- Da Vinci Surgical System$258
- FlowTriever$142
- ClotTriever$142
- VAPOTHERM$139
- Monarch Platform$120
- TAGRISSO$119
- Inspire$118
How this compares
$8,046 in reported general payments places this provider in the 75th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 34 | $963,243 |
| OfevNintedanib Esylate | 21 | $271,585 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 221 | $166,395 |
| AdempasRiociguat | 11 | $150,034 |
| CreonLipase/Protease/Amylase | 18 | $146,066 |
| Dupixent PenDupilumab | 28 | $104,337 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 69 | $48,353 |
| Breo ElliptaFluticasone/Vilanterol | 91 | $45,083 |
| Spiriva RespimatTiotropium Bromide | 46 | $37,806 |
| Ambrisentan | 12 | $36,913 |
| XolairOmalizumab | 14 | $32,703 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 45 | $30,749 |
| Advair HfaFluticasone Propion/Salmeterol | 24 | $15,973 |
| EliquisApixaban | 13 | $12,218 |
| BreynaBudesonide/Formoterol Fumarate | 59 | $9,932 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $437 | $963,24334 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $533 | $318,47382 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,165 | $249,956378 claims |
| BayerAdempas | $25 | $150,03411 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $576 | $53,89886 claims |
| Johnson & JohnsonXarelto | $252 | $5,96111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Long Beach
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.